Fenwick & West represented Elysium Health, a provider of scientifically-sound dietary supplements, in its $20 million Series B financing. General Catalyst led the round with participation from Breyer Capital, Morningside Ventures and Sound Ventures.
Elysium will use the funds to expand its operations to support its growing customer base. The company will also use the funds to initiate additional human clinical trials and support its mission to be a leader in the study of NAD+ and sirtuins within the context of human aging.
The Fenwick transaction team was led by corporate lawyers Matthew Rossiter, Thomas Kang and David He.